Xtant Medical

INVESTORS

HomeInvestors

INVESTORS

Click here for Webcast
Xtant Medical First Quarter 2026 Financial Results
 05/13/26  8:30 AM EDT

Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries.

 

 

 

Stock Quote

(Common Stock)
Price
Change (%)
Volume
Data as of  

Minimum 15 minutes delayed. Source: LSEG

Stock Chart

Recent News

Date Title  
Toggle Summary Xtant Medical Reports First Quarter 2026 Financial Results
Raises full-year 2026 revenue guidance to a range of $101-$105 million Significantly strengthens balance sheet Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST ® Bellows product for high-performance hemostasis; hires Dilon's U.S.
Toggle Summary Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026
BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc.   (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the first quarter ended March 31,
Toggle Summary Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped
BELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc.   (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of Trivium™ Shaped, an extension of its Trivium™ bone graft
Toggle Summary Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product
Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST ® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont. and NEWPORT NEWS, Va., April 13, 2026 /PRNewswire/ --  Xtant Medical Holdings, Inc.  (NYSE
More
Upcoming Events
There are currently no events scheduled.
More

Receive Email Alerts

Sign up to receive email alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your email address and click Submit.